ClinicalTrials.gg
RecruitingNCT07361562Updated Sep 4, 2026

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

A Phase 1 interventional study of CGT4255 in Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer and ERBB2 Gene Amplification, sponsored by Cogent Biosciences, Inc.. Recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Cogent Biosciences, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
1,056th of 2,998
100 · median 56
Started
2025
with 148 others
Phase 1
927 of 3,371
134 open now
Primary completion
2028-05
later than 599 of 892 live
Registered
3,253rd of 3,371
by date

Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,056th largest by planned enrollment of the 2,998 interventional ones that give a count, is one of 149 that started in 2025, is one of 927 in phase 1, reaches primary completion later than 599 of the 892 other live ones, and was the 3,253rd registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.

03

Conditions studied

  • Advanced Solid Tumor, Adult
  • ERBB2 Altered Breast Cancer
  • ERBB2 Gene Amplification
  • HER2 Overexpression
  • Non-Small Cell Lung Cancer
  • HER2

Keywords

  • ERBB2 genetic alterations
  • Investigational Drug
  • Advanced Solid Tumors
  • ERBB2 Mutated Non Small Cell Lung Cancer
  • Mutated Advanced Solid Tumors
  • ERBB2 Brain Metastases
  • ERRB2 Point Mutations
  • ERBB2 Gene Short Variants
  • ERBB2 Gene Rearrangements
  • ERBB2 activation alteration
  • ERBB2 gene copy number amplifications
  • ERBB2 gene insertions
  • ERRB2 gene deletions
  • ERBB2 gene fusions
  • NRG1 gene fusions
  • ERBB2 indel
  • Phase 1/1b
  • HER2 Protein Overexpression
  • HER2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have confirmed diagnosis of:

    1. Part A: Locally advanced, , and/or unresectable solid tumor with documented -activating alteration or NRG1 gene fusion in blood and/or tumor or HER2 overexpression in tumor
    2. Part B: Locally advanced, metastatic, and/or unresectable NSCLC with documented ERBB2 mutation in blood and/or tumor
    3. Part C: Locally advanced, metastatic and/or unresectable breast cancer with documented ERBB2 mutation in blood and/or tumor or HER overexpression in tumor
  2. Have per v1.1.
  3. (ECOG) Performance Status 0 to 1 for Part A. For Parts B and C, ECOG Performance Status must be 0 to 2.
  4. Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits.

Exclusion criteria

Exclusion Criteria:

  1. Received small molecule chemotherapy or anticancer therapies or radiotherapy within certain timeframes before first dose of study drug.
  2. Major surgeries (eg, craniotomy and thoracotomy) within 4 weeks of the first dose of study drug.
  3. Treatment with palliative focal radiotherapy (cranial or extracranial) (eg, stereotactic radiosurgery or intensity-modulated radiation therapy) ≤2 weeks before the first dose of study drug; treatment with whole-brain radiotherapy ≤4 weeks before the first dose of study drug.
  4. cardiac disease.
  5. Resolution of toxicities from prior therapy to ≤Grade 1 (or baseline), including resolution of clinically significant laboratory abnormalities, before the first dose of study drug.
  6. Restrictions on use of use to manage neurologic symptoms in different parts of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Part A: Dose Escalation Multiple doses of CGT4255 for oral administration

    Drug: CGT4255

  • Experimental
    Signal Seeking and Dose Escalation

    Part B: Signal Seeking and Dose Optimization Oral dose(s) of CGT4255 at the selected dose levels determined in Phase 1

    Drug: CGT4255

  • Experimental
    Signal Seeking

    Part C: Includes signal seeking. Participants will receive CGT4255 at a dose level selected based on data from Part A

    Drug: CGT4255

Interventions

  • DrugCGT4255

    CGT4255 Daily Oral Administration

06

What researchers measure

Primary outcomes

  1. Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Part A]

    1\. Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) and AEs leading to dose modifications and dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD) or the maximum evaluated dose (MED) in participants with ERBB2-altered advanced solid tumors

    Time frame: Approximately 12 months

  2. Overall Response Rate [Part B and Part C]

    Overall Response Rate (ORR), determined by confirmed CR + PR of all lesions (intracranial and extracranial), based on Investigator assessment using the whole-body RECIST v1.1 in participants with ERBB2-mutated NSCLC with Brain Metastases (BM) and in participants with ERBB2-mutated or HER2-positive breast cancer with BM ± leptomeningeal disease (LMD)

    Time frame: Approximately 6 months

Secondary outcomes

  1. Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Part B and C]

    Incidence and grade of Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs leading to dose modification in participants with ERBB2-mutated NSCLC with Brain Metastases (BM) and in participants with ERBB2-mutated or HER2-positive breast cancer with BM ± leptomeningeal disease (LMD)

    Time frame: Approximately 7 months

  2. Pharmacokinetics [Part A]

    Area under the concentration-time curve (AUC) in participants with ERBB2 altered advanced solid tumors

    Time frame: Approximately 28 days

  3. Pharmacokinetics [Part A]

    Maximum observed concentration (Cmax) in participants with ERBB2 altered advanced solid tumors

    Time frame: Approximately 28 days

  4. Pharmacokinetics [Part A]

    Observed concentration at pre-dose (Ctrough)

    Time frame: Approximately 28 days

  5. Pharmacokinetics [Part A)

    Time to measure concentration (Tmax)

    Time frame: Approximately 28 days

  6. Disease Response [Part A]

    Overall objective response rate (ORR), as determined by confirmed complete response (CR) + confirmed partial response (PR) of all lesions (intracranial and extracranial) based on Investigator assessment using whole-body Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    Time frame: Approximately 6 months

  7. Disease Response [Part A]

    Disease control rate (DCR), as determined by overall confirmed CR + confirmed PR + stable disease (SD) based on Investigator assessment using whole-body RECIST v1.1

    Time frame: Approximately 6 months

  8. Disease Response [Part B and Part C]

    Disease Control Rate (DCR), determined by overall confirmed CR + confirmed PR +SD based on Investigator assessment using whole body RECIST v1.1

    Time frame: Approximately 6 months

  9. Disease Response [Part B and Part C]

    Duration of Response (DOR), defined as time from first confirmed response (CR or PR) to the date of progressive disease (PD) or death from any cause, whichever occurs earlier

    Time frame: Approximately 6 months

  10. Disease Response [Part B and Part C]

    Progression- free survival (PFS), defined as the time from the date of the first dose of study drug (Part B run-in and Part C)/ randomization (Part B randomized cohort) until the date of PD, based on Investigator assessment using whole body RECIST v1.1, or death from any cause, whichever comes earlier

    Time frame: Approximately 6 months

07

Study locations

15 of 15 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for May 2028, 29 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 29 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Jan 23, 2026
StartActual
Dec 30, 2025
Primary completionEst.
May 2028
CompletionEst.
Nov 2028
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07361562
Lead sponsor
Cogent Biosciences, Inc.
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Dec 30, 2025
Primary completion
May 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Sep 4, 2026

Study contacts

Cogent Biosciences, Inc
Contact
trialinfo@cogentbio.com
617-945-5576

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion